ASKA Pharmaceutical Holdings

4886.TTSE PRIMEPharmaceutical

Financials · Standalone

Fiscal year ended	2026-03	2025-03	2024-03	2023-03	2022-03
Revenue	¥4.4bn	¥4.5bn	¥3.7bn	¥1.7bn	¥1.4bn
Operating income	¥2.7bn	¥3.2bn	¥2.5bn	¥658m	¥717m
Ordinary income	¥2.7bn	¥3.2bn	¥2.5bn	¥603m	¥717m
Total assets	¥52.4bn	¥48.3bn	¥43.2bn	¥41.6bn	¥41.3bn
Net assets / equity	¥45.5bn	¥44.6bn	¥42.7bn	¥40.9bn	¥40.7bn
EPS (basic)	¥83.99	¥111.57	¥87.1	¥20.95	¥23.79

From EDINET filings. Select any figure to open the report it came from. ^r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.

Reports · 13

All Annual 5 Half-year 2 Quarterly 62026 2025 2024 2023 2022

Period	Form	Filed	Figures
2025-04-01 → 2026-03-31	Annual	2026-06-19	203 figures · EDINET
2025-04-01 → 2025-09-30	Half-year	2025-11-07	71 figures · EDINET
2024-04-01 → 2025-03-31	Annual	2025-06-20	177 figures · EDINET
2024-04-01 → 2024-09-30	Half-year	2024-11-08	71 figures · EDINET
2023-04-01 → 2024-03-31	Annual	2024-06-25	151 figures · EDINET
2023-04-01 → 2023-12-31	Quarterly Q3	2024-02-09	49 figures · EDINET
2023-04-01 → 2023-09-30	Quarterly Q2	2023-11-10	73 figures · EDINET
2023-04-01 → 2023-06-30	Quarterly Q1	2023-08-07	47 figures · EDINET
2022-04-01 → 2023-03-31	Annual	2023-06-27	124 figures · EDINET
2022-04-01 → 2022-12-31	Quarterly Q3	2023-02-09	49 figures · EDINET
2022-04-01 → 2022-09-30	Quarterly Q2	2022-11-10	73 figures · EDINET
2022-04-01 → 2022-06-30	Quarterly Q1	2022-08-08	47 figures · EDINET
2021-04-01 → 2022-03-31	Annual	2022-06-28	63 figures · EDINET

6 more reports are still being processed.

Segments · FY ended 2026-03

Segment	External sales	Profit	Assets
Animal Health Business	¥7.3bn	¥344m	¥3.9bn
Oversea Business	¥4.6bn	¥108m	¥17.0bn
Pharmaceutical Business	¥58.9bn	¥7.1bn	¥49.1bn
Other segments	¥225m	−¥13m	¥58m
Adjustments & eliminations	—	−¥1.7bn	¥42.3bn
Total	¥71.1bn	¥7.6bn	¥70.1bn

Segment names from EDINET member IDs; not mapped to a common taxonomy.